Platform|API|Archive|Contact

Humanexa SignalsPharmaceutical Intelligence

FDA
EMA
MHRA
PMDA
Health Canada

Phase I
Phase II
Phase III
Readouts
Enrollment Signals

Pipeline Tracking
Company Moves
Asset Intelligence
Landscape Reports

Pricing
Access
Commercial
Launch Tracking

Licensing
Acquisitions
Partnerships
Capital Raises

Strategy Catalysts Pricing

Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

Regulatory
Clinical
Competitive
Markets
M&A Watch
Strategy
Catalyst Tracker

Company

Pricing
Partner with us
Subscribe
Contact
Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

Therapeutic Area

MEK Inhibitor

Therapeutic area intelligence for MEK Inhibitor with 6 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 6
Catalysts: 0
Companies: 3

Companies

Alembic Pharmaceuticals →

AstraZeneca →

Assets

Binimetinib →

Recent signals(6)

RegulatoryAugust 10, 2026

FDA Accepts Supplement for KOSELUGO (Selumetinib Sulfate) by AstraZeneca

The FDA has accepted a supplemental application (NDA213756) for KOSELUGO (selumetinib sulfate) from AstraZeneca, with a standard review priority.

August 10, 2026

AstraZeneca's KOSELUGO (selumetinib) NDA219943 receives AP status from FDA

AstraZeneca's NDA219943 for KOSELUGO (selumetinib) has received an Approval Pending (AP) status from the FDA.

RegulatoryAugust 6, 2026

FDA Accepts Supplemental NDA for Mekinist by Novartis

The FDA has accepted a supplemental NDA for Mekinist (trametinib dimethyl sulfoxide) submitted by Novartis.

RegulatoryJuly 20, 2026

FDA Accepts Supplemental Application for KOSELUGO (Selumetinib)

The FDA has accepted a supplemental application for KOSELUGO (selumetinib) submitted by AstraZeneca.

RegulatoryJuly 14, 2026

FDA Accepts Supplement for Mekinist (Trametinib) by Novartis

The FDA has accepted a supplemental application for Mekinist (trametinib) from Novartis.

StrategyJune 27, 2026

FDA Acceptance of Binimetinib Application by Alembic Pharmaceuticals

The FDA has accepted the application ANDA217678 for Binimetinib submitted by Alembic Pharmaceuticals.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

No related entities indexed yet.

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.